Regeneron Pharmaceuticals, Inc.
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

Last updated:

Abstract:

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

Status:
Grant
Type:

Utility

Filling date:

18 Dec 2019

Issue date:

27 Sep 2022